Neurologic

Alzheimer's Association International Conference (AAIC) 2026

Congress Details

July 12-15, 2026

London, United Kingdom

The material below is provided to support scientific exchange and pertains to select congress resources. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.

All congress materials are copyrighted by Alnylam. Permission is required to copy or distribute.

For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.

Agenda

13 July, 2026

Presentation Type

Poster

Time

07:30 - 16:15 BST

Location

Exhibit Hall

Title

Design of APPLAUDS, a Phase 2 Study of Mivelsiran in People With Down Syndrome and Early-Stage Alzheimer’s Disease

Presenter

Dr Michael Rafii

Alzheimer’s Therapeutic Research Institute, Keck School of Medicine, University of Southern California

CA, USA

AAIC_Sloan-Program-Overview-and-Phase-1_POS_D3_v5.0_23Jun26

Presentation Type

Poster

Time

07:30 - 16:15 BST

Location

Exhibit Hall

Title

ALN-5288, an Investigational RNA Interference Therapeutic Targeting MAPT in Phase 1 Development for Alzheimer’s Disease

Presenter

Kevin Sloan

Alnylam Pharmaceuticals
MA, USA

15 July, 2026

AAIC_Farley_Preclinical_POS_D3_v4.0_23Jun26

Presentation Type

Poster

Time

07:30 - 16:15 BST

Location

Exhibit Hall

Title

RNA Interference Knockdown of Microtubule-Associated Protein Tau (MAPT) as a Potential Therapeutic Strategy for Tauopathies: Preclinical Data in Rodents and Nonhuman Primates

Presenter

Jon Farley

Alnylam Pharmaceuticals
MA, USA